Format

Send to

Choose Destination
Endocr Res. 2015;40(3):133-8. doi: 10.3109/07435800.2014.966385. Epub 2014 Oct 20.

Short-term intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome.

Author information

1
Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana , Ljubljana , Slovenia.

Abstract

AIM:

Glucagon-like peptide 1 receptor agonists (GLP-1 RA) stimulate satiety leading to reductions in food intake and body weight. The effects of long- acting GLP-1 RA liraglutide on eating behavior of women with PCOS have not been investigated yet.

METHODS:

Thirty-six obese women with PCOS (mean ± SD, aged 31.2 ± 7.8 years, with BMI 38.7 ± 0.1 kg/m(2)), pretreated with metformin (1000 mg BID) were switched to liraglutide 1.2 mg QD sc for 12 weeks. Adiposity parameters and eating behavior as assessed by Three-Factor Eating Questionnaire (TFEQ-R18) were examined at baseline and after 12 weeks.

RESULTS:

Subjects treated with liraglutide lost on average 3.8 ± 0.1 kg (p < 0.001). Significant reductions of waist circumference and visceral adipose tissue (VAT) mass, volume and area were demonstrated from liraglutide induction to the end of the study. TFEQ-R18 scores were significantly different pre- and post-liraglutide intervention. After treatment with liraglutide the uncontrolled eating (UE) score decreased from 36.8 ± 24.5 to 19.6 ± 18.4 (p < 0.001) and emotional eating (EE) score decreased from 49.9 ± 33.3 to 28.5 ± 26.9 (p < 0.001). Scores for cognitive restraint (CR) were not changed.

CONCLUSIONS:

Short-term liraglutide treatment was associated with weight loss and significantly improved eating behavior in obese women with PCOS.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT01911468.

KEYWORDS:

Eating behavior; PCOS; TFEQ-R18; liraglutide; obesity

PMID:
25330463
DOI:
10.3109/07435800.2014.966385
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center